Search

Your search keyword '"Solanezumab"' showing total 291 results

Search Constraints

Start Over You searched for: Descriptor "Solanezumab" Remove constraint Descriptor: "Solanezumab"
291 results on '"Solanezumab"'

Search Results

1. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.

2. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.

4. Targeting amyloid β in Alzheimer's disease: Meta‐analysis of low‐dose solanezumab in Alzheimer's disease with mild dementia studies.

5. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis.

6. Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia

7. Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.

8. Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.

9. Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease.

10. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.

11. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.

12. Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review.

13. Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

14. More failure with solanezumab - this time in preclinical Alzheimer's disease.

15. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease

16. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

17. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.

18. Disease-modifying effect of solanezumab evaluated by delayed-start analysis in a Japanese subpopulation with mild Alzheimer's disease.

19. Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.

20. Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials

21. Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies

22. Passive antiamyloid immunotherapy for Alzheimerʼs disease

23. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease

24. Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy.

25. Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies.

26. Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment

27. Early Dementia Screening.

28. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.

29. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.

30. Critical Appraisal of Amyloid Lowering Agents in AD

31. Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity

32. Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease

33. Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia.

34. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.

35. Panel discussion: DIAN‐TU trial collaborative effort

36. Is it time to use predictive models to boost power of Alzheimer’s disease clinical trials? A post‐hoc analysis of phase 3 solanezumab trials

37. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab

38. Solanezumab in‐depth outcomes

39. Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease.

40. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.

41. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease

42. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

43. Recent advances and current perspectives in treatment of Alzheimer’s disease

44. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

45. Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

46. Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?

47. Grasping at straws: the failure of solanezumab to modify mild Alzheimer’s disease

48. This title is unavailable for guests, please login to see more information.

49. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.

50. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.

Catalog

Books, media, physical & digital resources